Share This Page
BENZAMYCIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Benzamycin, and when can generic versions of Benzamycin launch?
Benzamycin is a drug marketed by Valeant Intl and is included in one NDA.
The generic ingredient in BENZAMYCIN is benzoyl peroxide; erythromycin. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the benzoyl peroxide; erythromycin profile page.
US Patents and Regulatory Information for BENZAMYCIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valeant Intl | BENZAMYCIN | benzoyl peroxide; erythromycin | GEL;TOPICAL | 050557-001 | Oct 26, 1984 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Benzamycin (benzoyl peroxide + erythromycin): Investment Scenario and Fundamentals Analysis
Benzamycin (benzoyl peroxide/erythromycin) is a topical acne product with documented but non-dominant market and formulation-specific competitive pressure from newer topical and combination therapies. Investment attractiveness depends on (1) whether the product is still marketed in material jurisdictions, (2) the persistence of patent and regulatory exclusivity around the exact combination and formulation, and (3) the ability to defend against therapeutic substitution (topical retinoids, topical antibiotics with different regimens, fixed-dose combinations, and non-antibiotic anti-acne actives).
What is Benzamycin and how is it positioned clinically and commercially?
Benzamycin is a topical acne treatment combining benzoyl peroxide with erythromycin in a co-formulated drug product. The clinical rationale is dual action:
- Benzoyl peroxide: antibacterial activity and keratolytic effects that help reduce C. acnes and can mitigate antibiotic resistance pressure.
- Erythromycin: antibiotic activity against acne-related bacterial load.
From an investment lens, the core positioning risk is therapeutic substitution. Acne is a category where prescribers often move early to agents with durable benefit and lower resistance risk, such as topical retinoids and non-antibiotic combinations. The antibiotic component tends to face lower long-term preference in stewardship-guided treatment algorithms, which can compress unit economics versus newer entrants and reformulations.
Product scope (drug substance combination)
- Drug product: benzoyl peroxide + erythromycin (topical)
- Therapeutic area: acne vulgaris (OTC-to-prescription continuum varies by country; the product is generally prescription in major markets)
What does the patent and regulatory landscape imply for value capture?
Benzamycin is a combination product, and value capture typically hinges on: 1) protection of the specific fixed-dose co-formulation (composition/formulation patents), 2) protection of manufacturing process or stability innovations, 3) and any regulatory exclusivity (notably country-specific).
A key practical constraint for investors is that once a fixed-dose combination becomes generic-competitive in a jurisdiction, the opportunity is usually limited to:
- niche channel capture (dermatology prescribers or specific formularies),
- line extensions (strength changes, vehicles, or packaging),
- new dosing regimens or reformulated matrices,
- or differentiated life-cycle IP (new combination ratios or delivery systems).
Patent strategy implication (combination products)
Combination products create two distinct IP risk surfaces:
- Drug substance IP (benzoyl peroxide and erythromycin individually): typically not a major driver once molecules are old.
- Product-specific IP: formulation, ratio, vehicle, stability, and manufacturing. These tend to expire faster, which shifts the economic model toward brand equity and channel contracts rather than long-lived exclusivity.
How does competition and substitution affect fundamentals?
The fundamentals of Benzamycin are sensitive to substitution pressure because acne therapy is crowded and evolving. Competition is not only “same product, different brand.” It is:
- same therapeutic goal, different mechanism
- same mechanism, different regimen
- different product category rules (OTC switches, insurance coverage, and step-therapy)
Substitution vectors that typically compress pricing
- Topical retinoids and retinoid combinations
- Other antibiotic-containing topicals with different co-actives or stewardship positioning
- Non-antibiotic approaches that remove antibiotic-use friction for prescribers and payers
- Prescription-to-OTC shifts in some markets for benzoyl peroxide-based therapy (where regulatory pathways allow)
Competitive math for margins
Even if Benzamycin maintains share, the economic issue is usually:
- price erosion from generics and branded competitors,
- higher promotional costs to maintain dermatology mindshare,
- and increased formulary scrutiny on antibiotic-containing products.
In most acne categories, when generic competition intensifies, brand survival relies on either:
- demonstrable formulary listing advantages (tier positioning),
- superior tolerability that drives switching costs,
- or a differentiated vehicle that improves adherence.
What does utilization and prescribing behavior suggest about demand stability?
Acne treatment shows a repeat-therapy pattern, but the market is not linear because:
- patients often cycle among therapies due to irritation and adherence barriers,
- dermatologists and primary-care prescribers adjust based on severity and resistance concerns,
- payer policies increasingly push step therapy for acne.
Benzamycin’s long-term demand profile is therefore best understood as:
- stable but not high-growth, with demand largely dependent on ongoing prescribing and formulary access,
- vulnerable to share shift toward newer branded or combination products with strong evidence bases and better resistance stewardship framing.
What are the key investment scenarios?
Scenario 1: “Maintained share under generic pressure”
Core thesis: Benzamycin retains meaningful volume in dermatology channels, even as pricing trends downward.
Economic profile: modest revenue resilience; margin compression likely; investment returns depend on cost control, supply-chain efficiency, and channel economics.
Scenario 2: “Niche brand defense via tolerability and formulary wins”
Core thesis: a reformulated or packaged version improves tolerability and adherence, enabling better formulary retention and reduces switching to alternatives.
Economic profile: improved gross margin versus generic-only benchmarks; requires marketing and evidence support.
Scenario 3: “Exit or downscale due to substitution and contracting exclusivity”
Core thesis: therapeutic substitution plus loss of formulation-level exclusivity (or effective generic competition) causes sustained share decline.
Economic profile: declining revenue; valuation compression; focus shifts to remaining profitable markets or discontinuation.
What fundamental metrics should investors underwrite for Benzamycin?
Investors in a product with Benzamycin’s structure should underwrite a narrow set of hard drivers:
Market and pricing
- Net sales vs. gross-to-net erosion (rebates, chargebacks, discounts)
- Price per unit trend under generic entry or therapeutic substitution
- Net revenue retention on key formularies (top 20 plans or group purchasers)
Demand and channel
- Prescriber mix (dermatology vs. primary care)
- Refill patterns and persistence (time to discontinuation)
- Clinical switch drivers (irritation, inefficacy after a fixed trial window)
Supply and costs
- Manufacturing cost stability for fixed-dose combination co-formulation
- Stability and shelf-life constraints that affect returns and inventory risk
Regulatory and lifecycle
- Country-by-country status of approval and whether generics have launched against the exact combination
- Any product-specific regulatory exclusivity expiry dates that govern near-term competitive intensity
Where are the main risks?
1) Resistance and stewardship risk
Antibiotic-containing acne products face persistent long-term skepticism in stewardship programs. Even if efficacy is established, guideline drift and resistance management can reduce prescribing.
2) Formulary risk
Payers often prefer lower-cost regimens or broad formularies with non-antibiotic options. Antibiotic-containing fixed combinations can be relegated to lower tiers.
3) Generic and formulation-competition risk
Fixed-dose combination products are particularly exposed when formulation patents expire. Generic entrants can undercut branded economics while the clinical differentiation remains hard to demonstrate at payer level.
4) Patient tolerability risk
Benzoyl peroxide-based therapies can cause irritation, which drives discontinuation. If competing products reduce irritation (or use alternative vehicles), Benzamycin’s share may erode.
What is the “investment bottom line” for Benzamycin?
Benzamycin is best treated as a mature topical acne asset rather than a high-growth pipeline-like story. The investment case is strongest when:
- it still holds meaningful formulary access in key markets,
- it faces limited or slow-moving generic substitution in the specific combination and strength,
- and the company can defend gross margin via channel strategy and supply economics.
If those conditions weaken, the product typically behaves like a price-exposed category asset where upside is limited to execution (distribution, contracting, and cost).
Key Takeaways
- Benzamycin (benzoyl peroxide + erythromycin) is a mature acne combination with inherently higher long-term substitution pressure because it contains an antibiotic.
- Value capture is formulation- and jurisdiction-specific; once fixed-dose co-formulation protection erodes, economics trend toward price compression.
- The investment case hinges on formulary retention, net pricing dynamics, and whether the product maintains tolerability-led adherence advantages versus newer non-antibiotic or newer combination regimens.
- Treat Benzamycin as a defensive, channel-dependent asset unless there is active lifecycle differentiation (new strengths, vehicles, or regimen evidence that shifts payer behavior).
FAQs
1) Is Benzamycin a long-duration blockbuster type asset?
No. It is more consistent with mature, price-sensitive topical therapy economics where growth is typically constrained by substitution and generic pressure.
2) What drives Benzamycin share in dermatology?
Prescriber preference, tolerability profile, and formulary tier placement; resistance stewardship trends and guideline alignment also affect adoption.
3) Does the antibiotic component create specific investment risk?
Yes. Antibiotic-containing acne therapies face stewardship and guideline pressures that can reduce long-term prescribing and payer support.
4) What is the biggest swing factor for margins?
Gross-to-net erosion and price competition after generic or therapeutic substitution intensifies, especially in key payer contracts.
5) What lifecycle strategy can still improve economics?
New formulations or vehicles that reduce irritation, strengthen adherence, or enable stronger payer value narratives can support price retention, but the ceiling remains typical for mature topical acne categories.
References (APA)
- FDA. (n.d.). Drug approvals and databases for benzoyl peroxide/erythromycin products. U.S. Food and Drug Administration.
- EMA. (n.d.). European medicines database for topical acne combinations. European Medicines Agency.
- WHO. (n.d.). Antibiotic stewardship and resistance-related guidance relevant to antibiotic-containing therapeutics. World Health Organization.
More… ↓
